Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Rush Street Interactive Inc (RSI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Rush Street Interactive Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Rush Street Interactive Inc trades at $33.4 (market cap $3.44B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 11.6× Rush Street Interactive Inc's market cap, and Rush Street Interactive Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | RSI | |
|---|---|---|
Market Cap | $39.89B | $3.44B |
Sector | Health | Technology |
52-Week High | $491.22 | $33.40 |
52-Week Low | $278.09 | $14.51 |
Enterprise Value | $38.15B | $3.11B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
RSI stock trades at $33.40, up 2.36% today, with strong technical momentum and a bullish moving average signal. The company reported Q1 2026 EPS of $0.14, beating expectations, with revenue growth projected to $1.2B in 2026. Positive sentiment is driven by a 76.9% analyst buy rating and a $100M share repurchase program announced on May 5, 2026.
Outlook remains positive given earnings beats and growth initiatives, but high P/E of 98.24 signals valuation risk. Key risks include competitive pressures and reliance on sports betting trends. The consensus price target is $29.44, suggesting limited upside from current levels amid elevated expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Rush Street Interactive Inc
Rush Street Interactive, Inc. is a digital gaming and sports betting company operating in the regulated U.S. and international markets. The company owns and operates online casino (iGaming) and sports wagering platforms, including BetRivers and PlaySugarHouse brands. RSI focuses on providing a secure and high-quality online gaming experience, leveraging its proprietary technology platform and commitment to responsible gaming.
Read more on RSI →
